---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-204125"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-15T00:00:52.670490+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics signs manufacturing deal with Emergent for SAB-142; $36M minimum spend post-FDA approval

## Summary
- Master Manufacturing Services Agreement executed April 28, 2026, with Emergent BioSolutions Canada Inc. for SAB-142.
- Term runs 5 years from FDA approval; minimum aggregate spend of $36 million after approval.
- Emergent has exclusive manufacturing rights during term; SAB may seek alternative source in limited cases.
- Commercial batch price to be set in amendment within 18 months of anticipated commercial sale.

## SEC filing metadata
- accession: 0001193125-26-204125
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000119312526204125/0001193125-26-204125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000119312526204125/sabs-20260428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-204125
- JSON: https://secwatch.observer/filing/0001193125-26-204125.json
- Plain text: https://secwatch.observer/filing/0001193125-26-204125.txt

## Source-grounded claims
- claim_id: 6e02cb16cc75d5101d3020e599ef8fba4cf65870
  claim: SAB Biotherapeutics, Inc. entered into Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. valued at minimum aggregate spend following any FDA approval equal to $36 million (effective 2026-04-28).
  evidence_excerpt: On April 28, 2026 (the “Effective Date”), SAB Biotherapeutics, Inc., a Delaware corporation (the “Company” or “SAB BIO”) entered into a Master Manufacturing Services Agreement (the “MSA”) with Emergent BioSolutions Canada Inc. (“Emergent”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000119312526204125/0001193125-26-204125-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.